Toth Financial Advisory’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Toth Financial Advisory’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-150	Closed	-$1K	–	843
2021 Q3	$1K	Sell	150 -50	-25%	-$220	﹤0.01%	742
2021 Q2	$1K	Hold	200	–	–	﹤0.01%	684
2021 Q1	$1K	Hold	200	–	–	﹤0.01%	668
2020 Q4	$2K	Hold	200	–	–	﹤0.01%	562
2020 Q3	$2K	Buy	200 +50	+33%	+$379	﹤0.01%	508
2020 Q2	$1K	Hold	150	–	–	﹤0.01%	537
2020 Q1	$1K	Hold	150	–	–	﹤0.01%	447
2019 Q4	$1K	Buy	+150	New	+$1.36K	﹤0.01%	475

Other funds holding LOGC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

HCA

Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return

Toth Financial Advisory's LOGC Position: Q4 2021 in Review

Toth Financial Advisory sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2021, closing a stake of 150 shares — an estimated $1K sold.

Toth Financial Advisory first reported a position in LOGC in Q4 2019 and held it in 8 quarters. The position peaked at $2K in Q4 2020. 57 funds tracked by Wall St. Rank hold LOGC as of Q4 2021.

Toth Financial Advisory reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Toth Financial Advisory sold 150 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $1K.
Toth Financial Advisory first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2019 and held it in 8 quarters.
Toth Financial Advisory's LogicBio Therapeutics, Inc. Common Stock position peaked at $2K in Q4 2020.
57 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Toth Financial Advisory's 13F filing for Q4 2021, filed 31 Jan 2022.